Weight-loss drugs are all the rage on social media, but they could also provide the next big opportunity for private bank portfolios, with this market set to hit a US$100 billion valuation by 2030. While this industry is still emerging, Julius Baer is expecting significant revenue growth over the coming years, driven by rising obesity rates globally and tight supply of…
To access this content, please click back to the home screen, then click “Menu” (bars in top left bars) and then “Login”.
To enquire for a free trial, please start here.
Need more help? Click here or email [email protected].
To enquire for a free trial, please start here.
Need more help? Click here or email [email protected].
Subscriber Only Content
This article is available on a corporate subscription with Asian Private Banker. Please login or subscribe to view this content.
Need help? Please see our FAQ Guide or email [email protected]